Primaquine phosphate is indicated for the radical cure (prevention of relapse) of P. vivax and P. ovale malarias. Primaquine phosphate acts by interfering with parasite mitochondria, which is responsible for cellular energy supply; thereby, killing the parasite. The exact mechanism of anti-malarial action in primaquine phosphate has not been determined. It has been suggested that it may act by generating reactive oxygen species or by interfering with the electron transport in the malarial parasite. Primaquine phosphate may also act by binding to and altering the properties of protozoal DNA.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Primaquine Phosphate, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.